title: Neural control of lower urinary tract and targets for pharmacological therapy.
abstract: Studies on the physiology and pharmacology of the lower urinary tract have brought new information and concepts about the complex neural control of micturition. There are many mechanisms, some proven and others not yet completely understood, in which pharmacological agents may act facilitating the filling, storage, and emptying of the bladder. This review describes the peripheral innervation and the main pathways involved in lower urinary tract control. It also presents potential targets for the treatment of voiding dysfunctions.
authors.affiliation: Sector of Urogynecology and Vaginal Surgery, Department of Gynecology, Federal University of São Paulo, Rua Rodolfo Belz, 220/42A, São Paulo, 05639-010, SP, Brazil, maria.augusta@gmail.com.
authors.forename: Maria Augusta T
authors.initials: MA
authors.lastname: Bortolini
authors.forename: Andreisa P M
authors.initials: AP
authors.lastname: Bilhar
authors.forename: Rodrigo A
authors.initials: RA
authors.lastname: Castro
mesh_terms: D018663:Adrenergic Agents / Q000627:therapeutic use; D000344:Afferent Pathways; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D006801:Humans; D064729:Neurokinin-1 Receptor Antagonists / Q000627:therapeutic use; D009465:Neuromuscular Agents / Q000627:therapeutic use; D009482:Neurophysiology; D010275:Parasympathetic Nervous System; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D058920:Purinergic P2X Receptor Antagonists / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013564:Sympathetic Nervous System; D050916:TRPV Cation Channels / Q000819:agonists; D014521:Urethra / Q000294:innervation*; D001743:Urinary Bladder / Q000294:innervation*; D014554:Urination / Q000502:physiology*; D014555:Urination Disorders / Q000188:drug therapy*
chemical_list: D018663:Adrenergic Agents; D019274:Botulinum Toxins, Type A; D018680:Cholinergic Antagonists; D064729:Neurokinin-1 Receptor Antagonists; D009465:Neuromuscular Agents; D058986:Phosphodiesterase 5 Inhibitors; D011453:Prostaglandins; D058920:Purinergic P2X Receptor Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human